C-peptide (Connecting peptide insulin, Insulin C-peptide, Proinsulin C-peptide)
المؤلف:
Kathleen Deska Pagana, Timothy J. Pagana, Theresa Noel Pagana.
المصدر:
Mosbys diagnostic and laboratory test reference
الجزء والصفحة:
15th edition , p300-301
2025-11-25
49
Type of test Blood
Normal findings
Fasting: 0.78-1.89 ng/mL or 0.26-0.62 nmol/L (SI units)
1 hour after glucose load: 5-12 ng/mL
Test explanation and related physiology
In general, C-peptide levels correlate with insulin levels in the blood. The capacity of the pancreatic beta cells to secrete insulin can be evaluated by directly measuring either insulin or C-peptide. In most cases, direct measurement of insulin is more accurate. C-peptide levels, however, more accurately reflect islet cell function in the following situations:
• Patients with diabetes who are treated with exogenous insulin and who have antiinsulin antibodies.
• Patients who secretly administer insulin to themselves (factitious hypoglycemia). Insulin levels will be elevated. Direct insulin measurement in these patients tends to be high because the insulin measured is the self-administered exogenous insulin. But C-peptide levels in that same specimen will be low because exogenously administered insulin suppresses endogenous insulin (and C-peptide) production.
• Patients with diabetes who are taking insulin. This is done to see if the patient with diabetes is in remission and may not need exogenous insulin.
• Distinguishing type I from type 2 diabetes. This is particularly helpful in people who are newly diagnosed with diabetes. A person whose pancreas does not make any insulin (type 1 diabetes) has low levels of insulin and C-peptide. A person with type 2 diabetes has a normal or high level of C-peptide.
Furthermore, C-peptide is used in evaluating patients who are suspected of having an insulinoma. In patients with an autonomous secreting insulinoma, C-peptide levels are high. C-peptide can also be used to monitor treatment for insulinoma. A rise in C-peptide levels indicates a recurrence or progression of the insulinoma. In the same way, clinicians use C-peptide testing as an indicator of the adequacy of therapeutic surgical pancreatectomy in patients with pancreatic tumors. C-peptide can also be used to diagnose insulin resistance syndrome and to measure beta cell function after glucagon stimulation.
Interfering factors
• Because the majority of C-peptide is degraded in the kidney, renal failure can cause increased levels.
* Drugs that may cause increased levels of C-peptide include oral hypoglycemic agents (e.g., sulfonylureas).
Procedure and patient care
• See inside front cover for Routine Blood Testing.
• Fasting: yes
• Blood tube commonly used: red
Abnormal findings
Increased levels
- Insulinoma
- Renal failure
- Pancreas transplant
- Type 2 diabetes mellitus
Decreased levels
- Factitious hypoglycemia
- Radical pancreatectomy
- Type 1 diabetes mellitus
الاكثر قراءة في التحليلات المرضية
اخر الاخبار
اخبار العتبة العباسية المقدسة
